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Spermatogenic stem cell culturePurpose. The purpose of this review is to summarize science-based new treatments for human reproductive
failure and future developments. Results. First will be discussed popular but erroneous myths of current
non-science based treatments. Then will be discussed new treatments and their scientiﬁc base, including
ovary and egg freezing, and transplantation to preserve fertility in young women undergoing gonadotoxic
chemotherapy and radiation for cancer; new perspectives on human epididymal sperm maturation based
on a comparison between ICSI (intracytoplasmic sperm injection) with testis sperm versus epididymal
sperm; simplifying IVF and reducing cost by more intelligent and milder ovarian stimulation; improving
pregnancy rate in older women; searching the genome to ﬁnd genes which control spermatogenesis and
whose deletion or mutation causes spermatogenic failure; and human spermatogenic stem cell culture to
treat azoospermia, and to preserve fertility in pre-pubertal boys undergoing cancer treatment. Conclusion.
With stem cell biology and molecular understanding of reproductive failure, new therapies for previously
untreatable infertility are currently on the near horizon. Conversely our clinical results with new therapeutic
approaches are adding to our understanding of the basic science of reproduction. This article is part of a Spe-
cial Issue entitled: Molecular Genetics of Human Reproductive Failure.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The developed world is in the midst of a widespread infertility epi-
demic. Economies in Japan, the United States, southern Europe, and
even China are threatened by a decreasing population of young people
having to support an increasing population of elderly and retirees [1].
The most common reason to see a doctor in countries like India and
China, seemingly plaguedwith overpopulation, is for infertility. Infertil-
ity clinics are popping up throughout the world in huge numbers [2].
But much of the treatment is empirical, based on poor to no scientiﬁc
footing, and even lacks proper statistical evidence for effectiveness. In
most instances infertility is idiopathic, and there is even poor under-
standing of why IVF does or does not work in many cases [2,3].
2. Current treatments and myths
2.1. Male factor
We know that sperm counts can range from zero to 500,000,000 or
more per ml [4–7]. But we have no solid evidence for what is ther Genetics of Human Reproduc-
uite 730, St. Louis, MO 63017,
rights reserved.threshold, if any, for the sperm count to exceed in order to allow the
male to be fertile [4,5,7]. Yet billions of dollars are spent each year for
dubious treatments to try to increase the man's sperm count, ranging
from empirically placing him on Clomid, testosterone, HCG (human
chorionic gonadotropin), FSH (follicle stimulating hormone), aroma-
tase inhibitors, nutritional supplements, varicocelectomy surgery, cold
jock straps, abstinence until the time of ovulation, testosterone re-
bound, etc., all in a futile effort to raise a sperm count that cannot be
raised and which possibly does not need to be raised anyway [4–9].
Now it is true that microsurgery can correct obstruction like for a
vasectomy [10], and the very rare case of Kallmann Syndrome can
be corrected with gonadotropin administration; and ICSI (intra-
cytoplasmic sperm injection) with IVF and sperm retrieval are valid
treatments for azoospermia or the most severe oligospermia. But for
the most part, there is no scientiﬁc evidence for male infertility treat-
ment [2,5,11].
2.2. Female infertility
It is clear to all that the major reason for the world's growing infer-
tility epidemic is that as women put off childbearing, their eggs die off
and those that survive are of poor quality [12–15]. In her teen years a
woman has a 0.2% chance of being infertile, and by her early twenties
it is up to 2%. By her early thirties, it is up to 20% [2,16]. Most modern
women today do not think of having a baby until their mid-thirties,
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the decline in number of their oocytes. This is clearly demonstrated
by the high pregnancy rate using donor oocytes from young women
placed into the uterus of older women [2,3,16]. Yet fertility physicians
struggle to make a pathological entity diagnosis to explain the infer-
tility, which in truth in most cases is just a normal physiologic re-
sponse to oocyte aging [2,12,16].
What are some of the disastrous consequences of the empirical,
non-science based treatment of these misdiagnoses? Let's look at
“endometriosis” ﬁrst. Endometriosis simply means that there are small
pieces of endometrial tissue located in the pelvic peritoneum or in the
ovary, and there should be nothing surprising about this occurrence in
view of the commonality of retrogrademenstruation. Supposedly this ec-
topic endometrial tissue causes dysmenorrhea, although most periods
are painful in most women to some degree anyway, and endometriosis
is usually not the cause of these painful periods. But there has never
been an intelligent explanation forwhy these usually very small amounts
of ectopic endometrial tissue would cause infertility. Certainly the preg-
nancy rates using IVF for women with endometriosis are no lower than
for those without endometriosis [17]. Most randomized controlled stud-
ies fail to show a difference in pregnancy rates in couples with endome-
triosis who have or have not been treated for it [17].
But what is the danger of either an unwarranted varicoelectomy in a
male, or an ablation of endometriosis in a female? For varicocoelectomy,
it is easy to accidentally reduce the blood supply to the testicle or to
have lymphatic scrotal swelling, but most importantly, it delays the
IVF treatment with ICSI until the female partner's eggs are older and
less fertile [9,18]. For ablation of ovarian endometriosis, laparoscopic
stripping has been shown to reduce the ovarian reserve, even if
performed by experienced surgeons [19]. So in an effort to cure the en-
dometriosis, the female's ovarian reserve is almost always reduced.
Another popular but non-scientiﬁcally based treatment for the
human female involves PCOS (polycystic ovary syndrome). Metfor-
min is given to almost every non-ovulating woman with irregular cy-
cles under the assumption that PCOS is just another type of diabetes
mellitus. So these women, who have no glucose intolerance are com-
monly given a drug (which has huge side effects) that causes glucose
and potassium to go intracellular and rarely results in correction of
the failure to ovulate [20].
3. Science based major new therapies and new horizons
Aside from IVF and ICSI, which are long-term standardly accepted
treatments, the rest of this chapter will review new science based and
future therapies.
3.1. Preserving fertility for women who wish to put off childbearing or
who are about to undergo treatment with gonadotoxic drugs: using
ovarian freezing and transplantation
Until recently oocyte freezing had very poor to no success, and so
ovary tissue slow freezing was the only method we could rely upon
for preserving oocytes of patients with cancer prior to otherwise ster-
ilizing cancer treatment [21]. However, now we also have a favorable
option of retrieving oocytes after ovarian stimulation and egg retriev-
al, and using vitriﬁcation for cryopreservation [13,22]. Nonetheless,
ovarian tissue freezing and transplantation still has great advantages
over egg freezing in that there does not need to be a delaying stimu-
lation cycle prior to the cancer treatment. Furthermore, one cycle of
ovarian stimulation and egg freezing does not assume success of
pregnancy like an entire ovary would, and ﬁnally, transplanting ovar-
ian tissue back not only restores fertility but also endocrine function.
3.1.1. Fresh series of identical twins with POF
The ﬁrst successful fresh human ovary transplantation was
reported between a pair of remarkable monozygotic twins discordantfor premature ovarian failure (POF) using a cortical grafting tech-
nique [23]. The ﬁrst successful human frozen ovary auto-grafts were
reported around the same time with tissue cryopreserved for patients
with cancer prior to their sterilizing bone marrow transplants [24,25].
This followed similar results described in the sheep over a decade ear-
lier [21]. The technique has subsequently been reﬁned over a larger
series of nine consecutive successful fresh ovary transplants in identi-
cal twins (plus two fresh allotransplants to be treated separately),
with resumption of normal hormonal cycling and menstruation in
all cases, eventually leading to 14 pregnancies and 11 healthy babies
born from the nine fresh identical twin recipients [14,26–28]. This un-
usual consecutive series of fresh ovary cortical transplants helped us
also reﬁne the techniques necessary for successful preservation of
fertility for patients with cancer using ovarian tissue freezing, with
3 additional successful pregnancies from 3 frozen transplants. This
unusual series also helped to establish a method for distinguishing
between the egg loss from transplant ischemia versus the egg loss
from cryopreservation. We now can report long-term follow-up (up
to 8 years) of this original series of fresh transplants, and add to it
our more recent experience with cryopreserved ovarian tissue. The
results appear to be remarkably more robust than had originally
been contemplated [15,29].
The ﬁrst such twins case inquired about this possibility originally
from researching an earlier testis transplant we had reported for
anorchia [23,30,31]. From that point forward, patients in similar situ-
ations sought this treatment. The patients volunteered many reasons
for preferring transplantation over conventional oocyte donation.
Many of them had previous failures with donor oocyte IVF cycles,
and did not want to go through more IVF. Some had the opportunity
to donate an ovary at the same time as having surgery they required
for other gynecologic problems (such as ﬁbroids or cysts). All of them
found the possibility of natural conception more attractive than IVF or
egg donation. In most cases, the twins lived far apart (even in differ-
ent countries) and the donors preferred to make a single visit for a
one-time ovary donation, rather than go through multiple cycles of
ovarian hyperstimulation. We knew when we began this series that
there would be few clinical cases in the world like these that would
warrant fresh ovarian transplantation. However, this series would
allow us to learn how to more effectively freeze and transplant
human ovarian tissue, which would have far reaching consequences
and widespread application for preservation of fertility in cancer pa-
tients and for women who just need to delay childbearing for social
reasons. Despite risks, the evidence does not support a deleterious ef-
fect of unilateral oophorectomy either on fertility or on age of meno-
pause [32,33].
One entire ovary of the donorwas removed and the cortex dissected
away from the medulla. The cortex of the non-functioning recipient
ovary was removed in entirety, and the donor cortex slices were
transplanted onto the exposed recipient medulla using 9–0 nylon
interrupted sutures. A tiny piece of spare tissue of the donor, as well
as the entire resected atrophied ovarian cortex of the recipientwere ex-
amined histologically in all cases (Fig. 1a and b). Micro-hematoma for-
mation under the graft was avoided by micro-bipolar cautery and
micropressure stitches of 9–0 nylon. Constant pulsatile irrigation with
heparinized saline prevented adhesions (Fig. 2a–d). Only one-third of
the ovarian cortex was grafted fresh and two-thirds were frozen.
3.1.2. Ovarian cryopreservation
All of our fresh clinical transplant studies involved cryopreserva-
tion of spare tissue for future thawed transplants. We also have fro-
zen the ovarian tissue of 68 patients with cancer and 7 patients
who simply want to delay childbearing. All of the frozen cases thus
far transplanted back to the patient have utilized the slow freeze ap-
proach [21,34,35]. However, we now use vitriﬁcation exclusively for
cryopreservation in humans because of our in vitro viability analysis
studies as well as in vivo transplant studies in the bovine [14,36].
Fig. 1. (a) Showing the absence of primordial or preantral follicles in ovarian biopsies of this candidate for ovarian transplantation compared with (b) that in her fertile sister.
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were requesting fertility preservation by ovarian banking and who
consented to an oocyte viability test and histologic review of a small
sample (b10%) of their fresh or cryopreserved tissue. The goal of the
in vitro study was to determine which method produced a higher
cell survival rate. The high viability (92%) of oocytes in both control
(fresh) specimens and vitriﬁed specimens indicated that disaggrega-
tion per se had only caused minimal damage to this cell type [14].
Overall 2301 oocytes were examined from 16 specimens. Results
within each of the three groups revealed no signiﬁcant difference
overall between fresh and vitriﬁed tissue, but the viability of slow
freeze-cryopreserved tissue was less than half that of vitriﬁed tissue
or controls (42%) (Pb .01). Transmission electron microscopy also
has been used to analyze ovarian tissue that had been either
cryopreserved by slow freezing or vitriﬁed by ultra-rapid freezing,
showing vitriﬁcation to be superior [37]. Finally quantitative histolog-
ic study of primordial follicles in the bovine after vitriﬁcation andFig. 2. Steps in the procedure of ovarian transplantation between MZ twin sisters: (a) prep
recipient ovarian medulla; (c) attaching donor cortical tissue to recipient ovarian medulla;transplantation back to the cow twomonths later remarkably showed
no follicle loss.
The basic science concept of vitriﬁcation, whether for eggs, embry-
os, or tissue, is to completely avoid any ice crystal formation by using
a very high concentration of cryoprotectant and a very rapid rate
(virtually “instant”) of cooling. This is quite different from classic
slow freeze cooling which relies on a partial and very gradual removal
of water from the cell by encouraging ice crystal formation preferen-
tially on the outside of the cell, drawing the water out [36,38].
3.1.3. Cortical ovarian tissue transplant technique
Under general anesthesia, one ovary is removed from the donor
using laparoscopy or minilaparotomy. The whole ovary is transferred
to a Petri dish for dissection. It was felt important to prepare a cortical
tissue slice no thicker than ≅1.5 mm to facilitate rapid revasculariza-
tion while keeping the tissue constantly irrigated with ice-cold
Leibovitz L-15 medium (Fig. 2a). We now recommend a specialaration of donor ovarian cortex by dissection in a Petri dish on ice; (b) preparation of
(d) attaching thawed donor cortical tissue for re-transplant to the recipient medulla.
Fig. 3. Steps in the procedure of intact ovary microvascular transplantation: (a) micro-
surgical isolation of donor ovary blood supply; (b) end-to-end anastomosis of ovarian
blood vessel; (c) completed anastomosis of ovarian artery and veins.
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thinner slice. But for these initial fresh cases, the hand pared cortex
was divided into several pieces of approximately equal size for grafting,
one piece to each recipient ovary. The remaining two-thirds of the
cortical tissue was cryopreserved [21,34,35,39,40]. The technique for
transplanting thawed ovarian cortical tissue is no different than for
fresh cortical tissue.
The recipient ovarian cortex resected via minilaparotomy to lay
bare the medullary tissue (Fig. 2b); hemostasis is controlled with
microbipolar forceps, and pulsatile irrigation with heparinized saline
avoid adhesion formation or micro hematomas between donor and
recipient tissues. Avoiding microhematoma formation beneath the
graft may be the most important reason for minimal ischemic loss
of oocyte viability. The tissue graft is attached using 9–0 interrupted
sutures under an operating microscope (Fig. 2c). Very importantly,
the medullar bed is also sutured to the under surface of the cortical
graft with 9–0 sutures to maintain tight tissue approximation, again
to avoid microhematoma formation under the cortical graft (Fig. 2d).
3.1.4. Intact whole ovary transplantation
Before we had long-term follow-up of the cortical tissue grafts, we
had postulated, incorrectly we now believe, that we could lengthen
graft survival and avoid ischemic loss of follicles by doing instead a
whole intact ovary microvascular transplantation.
To transplant an intact whole ovary, the donor ovary is removed
by clamping the infundibular pelvic ligament at its base in order to
obtain maximum length. The veins (3–5 mm) are easily identiﬁed,
but the ovarian artery (.3 mm) is often not grossly visible. The entire
specimen is placed in Leibovitz medium at 4 °C and two veins and
one artery were dissected and isolated under the operating micro-
scope. The recipient's infundibular pelvic ligament is clamped at the
base and transected close to her non-functioning ovary. The donor's
ovarian veins are then anastomosed to the recipient's with 9–0
nylon interrupted sutures, and the ovarian arteries are anastomosed
with 10–0 nylon interrupted sutures (Fig. 3a–c). The original concept
behind whole intact ovary microvascular transplantation was to
avoid the supposed damage that was incorrectly attributed to cortical
grafting [41]. However, current results seem to eliminate the need for
whole ovary transplantation, as the much simpler fresh cortical ovar-
ian tissue grafts have now been shown to have a very long duration of
function.
3.1.5. Results of fresh and frozen ovarian transplantation
Results are summarized in Table 1 and in Figs. 4 and 5. All nine iden-
tical twin pairs underwent their orthotopic ovarian isotransplantation
between April 2004 and April 2008. The recipients, for the most part,
continued to cycle from two years in two patients whose donor had
low ovarian reserve to over seven years in most cases. The two whose
donor had low antral follicle counts (AFC) of less than 10, only func-
tioned for 2 years. However, even these two cases had spare frozen cor-
tical tissue that remains available for future transplants. Menstrual
cycles beganwithin 3 months, and Day 3 FSH levels returned to normal
by 4.5 months and ovulation resumed then in all cases (Figs. 4 and 5). A
total of 14 healthy babies resulted from the 12 ovary transplants, 11
from the 9 fresh transplants, and 3 from the three frozen transplants
(Table 1).
One of our identical twin recipients became pregnant at 39 years
of age (from a graft that was of course also 39 years of age), eight
months after transplantation. She delivered a healthy baby girl at
full-term and then conceived again at age 42 from the same graft,
and delivered a healthy baby boy, again at full-term, 4 years after
her transplant. Her ovary is still functioning to date after seven
years, and she conceived again at age 45 with another healthy boy,
more than seven years after her transplant. One case of ovary trans-
plant was an identical twin whose POF (premature ovarian failure)
was caused by a bone marrow transplant with pelvic irradiation forleukemia, with her identical twin sister being the donor. She became
spontaneously pregnant 5 months after her fresh ovary transplant
from her sister, but miscarried. Then at 1.5 years she became preg-
nant again and had a healthy baby, and at 5 years after the transplant,
she became pregnant again, and had a second healthy baby. Over
6 years later, her original transplant is still functioning, and she still
has 2/3 of an ovary that remains frozen. It does not appear from this
or from the frozen cases that transplant ischemia should limit the
duration of function or that pelvic radiation is incompatible with a
healthy pregnancy.
This newly favorable experience with ovarian cortex grafting is
not limited just to our center [42]. Equally robust results are being ex-
perienced in Brussels, Paris, Spain, Denmark, and Israel (personal
communication). Frozen ovarian grafts (even with the slow freeze
technique) in Denmark are lasting over 5 years and many spontane-
ous pregnancies have been reported with no need for IVF or other
ancillary treatment. At the time of this writing, 30 healthy babies
have been born from ovarian tissue grafting fresh and frozen, and
most involved no IVF, and resulted from just regular intercourse
with no special treatment (Table 2).
Table 1
Ovarian transplant results 14 babies (11 from 9 fresh; 3 from 3 frozen).
Pt # Age Pre-OP FSH Post-Op FSH Initial post-op menses intervals Preg Babies delivered Years of graft function
1 24 75 7.1 2nd baby: frozen 3 2 4
2 38 96 5.2 93, 42, 24, 27, 25… 3 3 >7
3 25 112 6.8 76, 23, 30, 26, 25, 26, 21, 24, 27, 34, 25, 27, 51, 30, 27, 26, 28, 19… 1 2 >6
4 34 58 9.4 81, 22, 47, 26, 21, 20, 27, 26… 2 1 4
5 40 60 6.8 86, 29, 38, 34, 28, 28, 31, 35, 34, 28, 33, 35, 30… 0 0 4
6 26 101 7.5 64, 20, 39, 40, 32, 26, 29, 26, 26, 41… 1 1 2
7 34 86 4.4 83, 22, 29, 29… 3 2 >6
8 37 86 7.4 100, 17, 39, 29, 27, 22, 23, 20, 34, 25, 26, 29… 1 1 >4
9 35 54 4.2 128, 42, 18, 25… 1 0 2
10 31 78 3.4 Frozen 1 1 2
11 33 85 8.6 Frozen 1 1 >1
Note: each graft represents only 1/3 of one ovary or 1/6 of entire ovarian reserve.
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The most common beneﬁt of ovarian transplant is not the unusual
cases of fresh grafting in identical twins but rather to protect the fer-
tility and future endocrine function of young women undergoing can-
cer treatment [14,36,43–49]. Since 1996, we have frozen ovary tissue
for 68 young women with cancer, or at risk for POF, of whom 16 had
spare frozen tissue subjected to detailed viability testing before cryo-
preservation and after thaw. All 68 had histologic review by a variety
of pathologists. Only one had ovarian metastasis, a young woman
with widespread breast cancer metastasis throughout her entire
body. Otherwise, none of our other 67 cases had any tumor cells in
their ovary as judged by microscopical analysis of histological sec-
tions. Andersen has also noted a complete lack of ovarian metastasis,
even in the majority of leukemia cases (Fig. 6) [50]. The reason for the
remarkable absence of ovarian metastasis might possibly be due to
the ﬁbrous avascular nature of the ovarian cortex. In fact, the reason
why fetal ovarian cords (which in the fetal male become seminiferous
tubules) invade the ﬁbrous cortex and become follicles, is that the
dense ﬁbrous tissue of the cortex (which in the fetal and adult testis
is just tunica albuginea) is needed to suppress the resting follicles
from developing all at once prematurely. By analogy, in the male,140
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Fig. 4. Recovery of ovarian function. The eight fresh transplant cases showed a dramatic dec
to the resumption of menses. The results of the microvascular whole-ovary transplant. Andleukemic cells do indeed routinely lodge in the testis proper, but
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protects these ovarian cortical slices as well.
3.1.7. Genetics of non-cancer premature ovarian failure, and low ovarian
reserve
Identical twins discordant for ovarian function present a true ge-
netic puzzle [33]. The great majority of women enter menopause in
their ﬁfth or sixth decade of life, at an average of 51 years, but 1%
undergo menopause quite prematurely, i.e. before 40 years of age
[51–53]. Premature ovarian failure (POF) is assumed to have a genetic
etiology and menopausal age normally is strongly heritable judging
by the greater concordance between monozygotic (MZ) than dizygotic
twins [54–57]. It was remarkable, therefore, to identifyMZ twin pairs in
which one sister had undergonemenopause for unexplained reasons at
a very early age from 14 to 22 years, whereas the other, was still fertile
with naturally conceived children, as well as normal ovulatory cycles
and ovarian reserve [23,26–28].
We have not yet taken advantage of the unique opportunity these
twins offered for studying the genetic origin of ovarian reserve, but
genomic DNA and lymphoblastoid cell lines were prepared and of Ovarian Function
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obstetric records on the original chorionicity at birth of these identical
twin sisters revealed 50% were monochorionic–monoamniotic, which
was surprisingly high since the incidence of mono/mono is normally
only ≈2% (Pb0.0005). It is clear that late splitting of the inner cell
mass of the blastocyst, for whatever reason, predisposes otherwise
identical twins to discordant germ cell deﬁciency [27,58,59].
Thus far the search for genes controlling ovarian reserve in the
human has yielded meager results, the only modestly common candi-
date being the pre-mutation carrier status for fragile X (FMR1). The an-
swer oddly enough may lie in a search for genes on the X-chromosome
analogous to the search that has been conducted for genes on the
Y-chromosome that control spermatogenesis (see below). The human
Y-chromosome contains a huge concentration of amplicons and palin-
dromes, which are very difﬁcult to sequence [8]. These regions of long
sequence identity with many multi-copy genes, would not have been
sequenced with routine methods and most would have been missed
in the sequencing without special methodology. Similar regions on
the X chromosome that did not undergo the very specialized type of
sequencing used for the Y would not have been elicited in the
genome sequence yet. I would speculated that repetitive regions on
the X-chromosome would be a very attractive place to ﬁnd genes
which control ovarian reserve and maybe even genes that control
spermatogenesis.
3.1.8. Future prospects for ovarian tissue transplantation
After ovarian transplantation, the patients were able to attempt
natural conception every month without medical assistance andTable 2
Worldwide frozen ovarian cortex tissue transplant pregnancies.
Case # Diagnosis Babies Where
1 Hodgkins 1 Donnez
2 Neuro tumor 1 Donnez
3 Non-Hodgkins 1 Meirow
4 Hodgkins 1 Demeestere
5 Ewings 3 Andersen
6 Hodgkins 1 Andersen
7 POF 1 Silber
8 Hodgkins 2 Silber
9 Polyangitis 1 Piver
10 Breast cancer 2 Pellicer
11 Sickle cell 1 Piver
12 Hodgkins 2 Revel
Totals: 12 patients 17 babies 8 centers
Fresh+Frozen 28 babies Silber—14 babiesheterotopic sites have produced no successful pregnancies to date.
Our patients preferred the chance of natural conception anyway
[39,40,60,61]. In fact, the commonly held view that egg freezing is a
proven technique and ovary tissue transplantation is “experimental,”
is belied by the fact that all of the successful pregnancies resulting
from fertility preservation in patients with cancer thus far have
been from frozen ovary tissue, and none at the date of this writing
have come from frozen oocytes [42].
It is generally assumed that premature ovarian failure or low ovar-
ian reserve is related to the number of primordial follicles the woman
has at birth and this number is certainly heritable and is most likely
genetically determined [59]. All modern women are concerned
about what is commonly referred to as their “biological clock” as
they worry about the chances of conceiving by the time they have
established their career and/or their marriage and their ﬁnancial sta-
bility. Most of our cured patients with cancer, who have “young”
ovarian tissue frozen, feel almost grateful they had cancer, because
otherwise they would share this same fear all modern, liberated
women have about their “biological clock.”
For patients with leukemia, or any patients inwhom transplantation
of prior frozen ovarian tissue might create a risk of re-introducing can-
cer cells, we recommend that before the cortical tissue is dissected and
frozen, that all the antral follicles of the removed ovary be aspirated for
germinal vesicle oocyte (GV) retrieval. These GV's can then be partiallyFig. 6. All the primordial follicles of the ovary are located in the outer 0.75 mm of the
cortex. Therefore, very thin slices of cortex will contain all these follicles and allow
rapid revascularization.
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a few minor modiﬁcations) (See Fig. 7). Allografts might be considered
if ovarian tissue is available from a young woman who previously do-
nated bone marrow to the same patient [62].
At the time of this writing, we are aware of numerous other births
after implanting ovarian tissue for a total of 28 live births thus far
[24,25,42,63–66]. Thus, despite initial skepticism, this technique is
now gaining worldwide acceptance, and is being enthusiastically re-
ceived by young women of reproductive age with cancer.
3.2. Egg and embryo vitriﬁcation
Vitriﬁcation for freezing eggs or embryos was ﬁrst suggested in
the mid-1980s [66,67]. However, it was not until 2005 that a highly
efﬁcient method was published, which stimulated a huge wave of
justiﬁed enthusiasm for this approach to egg and embryo freezing
[13,22,68,69]. The concept behind vitriﬁcation is not just its potential
simplicity (like no freezing machine is required) but that could
eliminate ice crystal formation completely. Instead of clinical IVF pro-
grams having to weigh carefully the risks to healthy pregnancy posed
by embryo-freezing, embryos could be frozen without concern in vir-
tually any case in which there would be a clinical advantage. With the
new vitriﬁcation methodology, there is no difference in implantation
potential between fresh and frozen embryos.
The vitriﬁcation protocol was designed to avoid too rapid osmotic
shifts that could be caused by such high concentrations of cryoprotec-
tant [22]. The ultra-rapid rate of cooling (−23,000 °C per minute)
and the high concentration of cryoprotectant lower the freezing
point dramatically and allows the ice crystallization phase to be
completely avoided.
3.3. Mini-IVF with less cost and high success rates for older women
With more innovative stimulation protocols, using mild increases
only in FSH level to produce a smaller number of better quality eggs,
IVF not only becomes less formidable, but also yields a solution to the
very obsessive question of how better IVF results can be achieved in
older women. In this unusual protocol, clomiphene citrate, a compet-
itive inhibitor of oestradiol, is used to stimulate the ovary by gently
elevating FSH secretion of the pituitary gland. Continuation of clomi-
phene citrate beyond the usual 5 days is also able to inhibit the
LH surge [70,71]. Thus, a longer stimulation can be achieved with
clomiphene citrate and a premature LH surge can be prevented by
the antioestrogen effect of clomiphene on the pituitary when theFig. 7. Partial cumulus denudation prior to vitriﬁcation of GV oocytes.oestradiol begins to rise. Once adequate follicle development is
noted, a gonadotrophin-releasing hormone agonist (GnRHa) is ad-
ministered to trigger an LH surge for the ﬁnal maturation of oocytes.
This protocol is often referred to as mini-IVF [70,71].
There have been several reports of improved egg quality in IVF
protocols with less medication [72–83]. Mini-IVF is less expensive
and easier for the patient. With less follicles to aspirate and less
eggs for the laboratory to manage, many more procedures can be
performed with less effort and less cost [70,77,79,84]. The question
is whether the already-demonstrated improvement in percentage of
good-quality embryos with a mild stimulation protocol is sufﬁcient
to outweigh the larger number of eggs obtained with conventional
stimulation [75,82]. Another more interesting question is if better re-
sults can be obtained in older women.
Is it really possible to achieve pregnancy rates with retrieval of
only two or three eggs with mini-IVF that are comparable to what
can be achieved with 10–20 eggs using conventional stimulation pro-
tocols, and more important can we improve results in older females?
There are many reasons for using GnRHa to trigger ovulation. It
stimulates the pituitary to produce a more natural surge of LH and
is potent enough to induce maturation in larger follicles. Its half-life
is short and so it never stimulates small follicles. This allows the
body to preserve those smaller follicles for upcoming cycles, rather
than stimulate them prematurely, and allows women to cycle repeat-
edly without taking breaks. This is especially advantageous for older
patients having limited ovarian reserve. In addition, avoiding the
use of HCG also reduces the incidence of ovarian hyperstimulation
syndrome (OHSS) [85–88]. All these reasons favor the use of GnRHa
over the conventional use of HCG for triggering egg maturation.
The reliance on continuous clomiphene citrate, with its negative
impact on the endometrium, required a simpliﬁed, cheap, reliable
method for embryo cryopreservation, for which we chose the
Kuwayama method [22,67]. The vitriﬁcation protocol was developed
to overcome the deleterious effects of ice crystal formation that oc-
curs during the slow-freezing method. With conventional slow freez-
ing, the temperature is gradually dropped −0.3 °C per minute to
create preferential ice crystal formation outside the cell. But this ap-
proach only reduces the cellular water content from 70% to 30%;
there is still a fair amount of ice crystal formation intracellularly. In
vitriﬁcation, the temperature drop is −23,000 °C per minute and
there is no ice crystal formation whatsoever. So vitriﬁcation depends
on a faster cooling rate with a higher viscosity of cryoprotectant and a
miniscule cryosolution volume to get the most rapid temperatue drop
and prevent ice crystal formation inside and outside the cytoplasm of
the cell. Vitriﬁcation increases the possibility of using a single-embryo
transfer protocol, because there is no urge from the patient to transfer
more than one embryo for fear that her results with fresh embryos
will be better than with cryopreserved. Furthermore, it is cheaper
and easier than the conventional slow freeze methods.
In summary, maximal ovarian stimulation, which produces large
numbers of eggs, results in a lower percentage of good-quality eggs
(deﬁned as implantation rate per egg) than gentle ovarian stimula-
tion which produces fewer eggs [73,81,82]. Most importantly for
older women, multiple cycles of mini-IVF with better quality embryos
because of less FSH elevation give them a better result than maximal
dose gonadotropins.
3.4. Intra-cytoplasmic sperm injection (ICSI) for azoospermic men and
implications for sperm maturation
It is unknown howMESA (epididymal sperm) and TESE (testicular
sperm) compare in terms of pregnancy rate in couples with azoosper-
mia. It is also unknown whether surgically retrieved sperm has simi-
lar or worse results than ejaculated sperm either in men with low
sperm count or normospermic men. Ever since ICSI was ﬁrst intro-
duced, it has been assumed that the source of the sperm does not
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unclear whether the degree of spermatogenic defect has an impact on
chance of pregnancy. In fact, some urologists proclaim that testis
sperm is even better than ejaculated sperm and recommend TESE
even when there are a few sperm in the ejaculate. This has important
implications for the basic science of sperm maturation and its impact
on embryo development.
We have not yet published, but have presented some interesting
speculations from human results that support the concept that
sperm do mature functionally when they exit the testis. We studied
374 consecutive ICSI cycles of men with obstructive azoospermia
using TESE (testicular) or MESA (epididymal) sperm, and 1849 con-
secutive unselected cycles ICSI cycles of men without azoospermia
using ejaculated sperm. The purpose of this study in which all pa-
tients underwent ICSI, was to determine the results with ICSI of
ejaculated sperm versus epididymal sperm (MESA) versus testicular
sperm (TESE), regardless of the spermatogenic defect.
Interestingly, we found that the MESA-ICSI cycles resulted in a sig-
niﬁcantly higher implantation rate, and signiﬁcantly more clinical and
ongoing pregnancies than the TESE-ICSI cycles. The results for
TESE-ICSI in these men with obstructive azoospermia were similar
to our results of TESE-ICSI in men with non-obstructive azoospermia.
We also found no difference in results for any category of sperm
count so long as ejaculated sperm were used. Furthermore, there
was no difference in results between ejaculated sperm and MESA
sperm. Thus, spermatogenic quantity was not an important variable,
but testicular sperm seems to be inferior to both epididymal and ejac-
ulated sperm (which are equivalent to each other). The reason that
many IVF programs have poor results with epididymal sperm could
be that they obtain distal sperm under the misconception that it is
more mature. But in the obstructed epididymis, the distal sperm are
more senescent and so the proximal most sperm surprisingly are
the freshest, and will yield the best results [89].
3.4.1. Microsurgical TESE
NOA is due to a severe quantitative spermatogenic defect wherein
there is not enough quantity of sperm production to “spill over” into
the ejaculate whereas OA is associated with normal spermatogenesis
[8,89–108] (Figs. 8a and b, 9a and b). For non-obstructive azoosper-
mia, epididymal sperm can never be retrieved, because the walls are
collapsed and there is no obstruction to allow epididymal sperm col-
lection to take place [97]. For non-obstructive azoospermia, an open
testicular biopsy is performed under the microscope with the sameFig. 8. A diagram of the serial transection of the epididymis in a patient who had undergone
ymis, secondary epididymal obstruction is bypassed and then normal motile sperm are seetype of local anaesthetic as for MESA, with the patient wide-awake,
and with minimum postoperative discomfort.
When extensive multiple biopsies from every area of the testis are
performed in an effort to ﬁnd sufﬁcient sperm for TESE, a great deal of
testicular damage can result, and may limit “successful” patients to
only one attempt [109,110]. An attempt to limit damage by using
multiple needle sticks rather than open biopsy to obtain sperm for
ICSI is just as invasive and quite risky as well. Furthermore, control
studies have shown that for difﬁcult cases of non-obstructive azoo-
spermia, where there is very limited spermatogenesis, needle biopsy
is much less likely to ﬁnd the rare foci of spermatogenesis than open
biopsy [111,112].
The solution to cases where there are no sperm to be seen on TESE
is not to look for “round spermatids” [102,113,114]. We never see
round spermatids in the absence of mature spermatids, which at
TESE are what just appear to be sperm [102,113,115–119]. The solu-
tion is to search for the few sperm with tails that are very sparsely
and diffusely present.
3.4.2. Conclusions
It has been well shown over the last four decades that testis sperm
undergo remarkable changes when they passage into the epididymis.
Still, many andrologists have wrongfully assumed that ICSI completely
avoids that need for sperm maturation. Our results indeed, do show
that ICSI does not completely bypass the beneﬁts of sperm passage
into the epididymis, and it would be beneﬁcial if sperm production
could be increased enough in NOA for there to be sperm in the epidid-
ymis or ejaculate (see the last section on spermatogenic stem cells).
3.5. Sequencing the X and Y chromosome in azoospermic men to identify
genetic control of spermatogenesis
In 1993, we began to study the genetic causes of male infertility
via the ﬁrst mapping of the Y chromosome in azoospermic males
and in fertile control male populations, eventually leading to com-
plete sequencing of the Y chromosome. This led to a better under-
standing of why tiny amounts of sperm are often found in the testis
of azoospermic men previously thought to be making no sperm
[120–127]. This ongoing genetic study of male infertility has helped
to squelch the foolish but clinically popular (and wasteful) idea that
hormones or varicocelectomy can improve sperm count, which is
for the most part genetically determined. This specialized male chro-
mosome, the Y chromosome, contains many genes that are involvedvasectomy but has n o sperm in the vas ﬂuid. At some point proximally in the epidid-
n.
Fig. 9. A diagram of the serial transection of the epididymis in a patient who had undergone vasectomy but has no sperm in the vas ﬂuid. At some point proximally in the epidid-
ymis, secondary epididymal obstruction is bypassed and then normal motile sperm are seen.
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repeats and mirror image inversions called amplicons and palin-
dromes. Deletions involving these regions of the Y are found in 15%
of severely infertile males and have been shown to be transmitted
to male offspring via ICSI, presumably causing fertility problems in
these children later in life [124,128,129]. Early mapping of these dele-
tions were subsequently elaborated in greater detail by sequencing of
the entire Y chromosome (Fig. 10).
The sequence of the Y also gives us a perspective about other male
infertility genes that are widespread throughout the genome. More
importantly perhaps, understanding the Y chromosome helps us to
comprehend why men who are seemingly azoospermic often have
some residual tiny amount of spermatogenesis that can be used for
successful ICSI [97,100,130]. Many genes on the Y required for sper-
matogenesis have multiple copies, and even have “backup” homo-
logues elsewhere in the genome, like DAZL and CDYL [8,131,132].
Another broader scientiﬁc beneﬁt is that it has ampliﬁed our under-
standing of sex determination in general, and has even helped to ex-
plain the origin of Turner Syndrome [133]. Indeed, studies of male
infertility and the Y chromosome have gone so far as to show why
XO Turner females are not generally caused by the loss of an X chro-
mosome in the female embryo, but rather by a loss of the Y chromo-
some in a male embryo.
Suspicion of involvement of the Y chromosome in male infertility
actually arose originally from cytogenetic evidence reported over
35 years ago [134]. This karyotyping study showed grossly obvious
terminal Y chromosome deletions in a very small percentage (0.5%)
of azoospermic men who were otherwise phenotypically normal.
During the mid-1990s, it was shown that the long arm of the Y chro-
mosome indeed does contain not one but many distinct deletion in-
tervals and at least 60 genes belonging to nine gene families whose
exclusive function is in spermatogenesis [120–123,125–127,135].
The Y deletions have been divided clinically into three groups, but
this classiﬁcation is actually naïve in most instances.3.5.1. AZFa
The AZFa region differs from the AZFb and AZFc regions because of
its non-repetitive structure and its low deletion frequency (Fig. 11).
AZFa deletions are very uncommon and only a few rare patients
have been described [135–140]. However, studies of this region are
highly useful in understanding the genetic basis of male infertility.
The AZFa region spans ~800 kilobases (kb) and contains two func-
tional single-copy genes: USP9Y and DBY [140,141]. A point mutation
in USP9Y represented the ﬁrst case of a point mutation rather than a
large micro-deletion on the Y chromosome associated with sper-
matogenic failure [140]. The lack of sequence repeats which plaguethe rest of the Y chromosome, made this particular region of the Y
amenable to such a point mutation search.
The AZFa region provides a good model for the interaction and
overlapping functions of multiple genes, which sheds light on the
polygenic nature of the genetic control of spermatogenesis. When
the entire AZFa region is deleted, taking out both DBY and USP9Y,
the spermatogenic defect is severe and the patient is always
azoospermic. In contrast, when only one gene is affected, such as in
the patient with loss of USP9Y function due to a speciﬁc point muta-
tion, this results in a less severe phenotype of maturation arrest
with a few pachytene spermatocytes developing into a few mature
sperm in some seminiferous tubules.
3.5.2. AZFb
Deletions of the AZFb region are slightly more common than dele-
tions of the AZFa region but are still found in a very small percent of
azoospermic men [135,142–145]. Interestingly, all men with dele-
tions of AZFb described to date are azoospermic and also show
complete absence of spermatozoa in the testis [131,135,143–150].
Therefore, similar to AZFa deletions, there are no reports on transmis-
sion of an AZFb deletion to ICSI offspring. Many functionally active
genes are clustered within the AZFb region [147,151,152]. Because
of the presence of multiple sequence repeats within this region, in
contrast to AZFa, efforts to deﬁne the AZFb region precisely had
been hampered until more recently [127,143].
In fact, the region frequently referred to simplistically as AZFb
overlaps AZFc and has a massive number of repeat copies of genes
and pseudogenes (RBMY, PRY, TTTY) arranged in a complex of palin-
dromes (inverted repeat sequences). That is why we technically object
to this commonly used terminology of “AZFb” and prefer to refer to the
P5/P1 deletion.
3.5.3. AZFc
The most commonly deleted and best-studied region on the Y
chromosome is the AZFc region. Deletion of the AZFc region is found
in approximately 12% of azoospermic men and in 6% of severely
oligozoospermic men [8,120–122,153]. This region is constructed
from massive areas of absolute sequence identity called amplicons
which are arranged in direct repeats, and inverted repeats, or palin-
dromes. The AZFc region spans 3.5 Mb (huge but not quite as huge
as AZFb with its massive 8 Mb length), and contains seven separate
families of genes with a total of 19 genes that are all exclusively
expressed in the testis. Once called a “microdeletion,” AZFc, is actually
a huge section of DNA, but just not huge enough to show up with
karyotyping. Interestingly, absence of this large 3.5-Mb AZFc chunk
of the Y chromosome, as well as the much larger even AZFb region,
seems to have no other deleterious effect on the male except upon
Fig. 10. Early map of major Y chromosome deletions in azoospermic men and the diversity of pathologic defects [118].
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of this region of the Y chromosome [121]. These genes only affect
spermatogenesis and nothing else.
The DAZ gene family, which is one of the seven gene families locat-
ed within AZFc, was one of the ﬁrst spermatogenesis genes identiﬁedFig. 11. Simpliﬁed diagram of the main areas for Y chromosome microdeletions, in-
cluding some that are less frequently studied, such as b2–b3 [140].on the human Y chromosome and comes in four almost identical cop-
ies [120,125]. The human DAZ genes were shown to be transcribed
speciﬁcally in spermatogonia and in early primary spermatocytes
[154]. Interestingly, autosomal homologues of DAZ in other species
were also shown to be involved in control of spermatogenesis,
supporting an essential role of this gene in male fertility in humans
as well as almost all other animals. Autosomal homologues of DAZ
have been found in Drosophila (termed Boule), in mice (termed
Dazl), in frogs (termed Xdazl) and even in worms (termed daz-1)
[155–160]. Therefore, DAZ is the most ancient and well conserved
spermatogenesis gene. In contrast to humans, the DAZ gene in these
other species is single copy and located on an autosome rather than
on the Y chromosome.
The human also retains an autosomal homologue of DAZ called
DAZL, which is located on chromosome 3 [125]. During evolution,
sometime after the split of Old and New World monkeys approxi-
mately 30 million years ago, the DAZL gene was transposed to the Y
chromosome like a simple translocation event. Once autosomal
DAZL was transposed from chromosome 3 to the Y, it was ampliﬁed
into four copies. The exact interaction and possible functional overlap
between these members of this interesting gene family perhaps holds
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of azoospermic men because of genetic “backup.”
The Y chromosome, with its lack of recombination during meiosis,
represents a safe harbor for the proliferation of genes that are beneﬁ-
cial to the male but detrimental to the female. This is how the Y chro-
mosome, over evolutionary time, tends to accumulate genes from
throughout the entire rest of the genome that control spermatogene-
sis. A degradation of its X homologues due to failure of recombination
occurs at the same time.
Deletions of the entire AZFc region result in loss of all four DAZ
copies, but most of these men still have some minute amount of sper-
matogenesis, speculatively because of backup from DAZL on chromo-
some 3. Men with a deletion of only two DAZ genes are less affected
than men with a deletion of all four copies [161–165]. Disruption of
different genes or disruption of some genes of a gene family can result
in different degrees of spermatogenic failure.
3.5.4. Mechanism of de-novo Y chromosome deletions
Deletions of the Y are caused by “illegitimate” homologous recom-
bination between highly similar or identical sequences, which are
found on the Y in great abundance. For example, homologous recom-
bination between two identical sequence stretches results in dropout
of the intervening AZFa region [141,166,167]. Since these sequences
of identical nucleotide repeats are shorter than those in AZFc or
AZFb, AZFa deletions are very rare. For AZFc the substrates for homol-
ogous recombination are two repeats that are over 99.9% identical
and as long as 229 kb in length [121]. Therefore, deletions of AZFc,
caused by homologous recombination between 229 kb repeats, are
far more common than deletions of AZFawhich are caused by repeats
of only 10 kb in length. The very repetitive nature of the Y chromo-
some seems to be the cause of its instability over an evolutionary
time frame, but it is also the method that the Y has adopted (albeit in-
efﬁcient) for its survival, called “gene conversion” [168].
What is equally fascinating is how we survived at all, as our X ho-
mologous genes on the Y chromosome deteriorated because of failure
of meiosis with its non-recombiningmate [169,170]. In fact, this deteri-
oration of X homologous Y genes was the whole reason for the evolu-
tion of “X inactivation,” to put males and females on an equal footing
despite different gene dosages. This gives us a better understanding of
the evolution in time over and over again of sex chromosomes.
3.5.5. Evolution and genetic constitution of the human Y chromosome
Over the past 240–320 million years of mammalian evolution, the
X and Y chromosomes have evolved from what was originally a pair
of ordinary autosomes about the size of chromosome 7 or 8. During
that evolution, just as most of the ancestral X genes were decaying
on the Y because of the lack of meiotic recombination, at the same
time genes which control spermatogenesis arrived on the Y from au-
tosomes. Once on the Y, these formerly autosomal genes ampliﬁed
into multiple copies, and inversions through the process called
“gene conversion” [125,168,171]. Other spermatogenesis genes on
the Y actually originated there, such as RBMY, and have persisted in
their original position as on the X [172–175]. The ancestral gene
that remained on the X chromosome (RBMX) retained its widespread
cellular functions, whereas RBMY, which persisted on the receding Y
chromosome, evolved a male-speciﬁc function in spermatogenesis
again because of the advantage of having male speciﬁc genes on a
chromosome found only in males [174,176–178].
How does the male speciﬁc Y survive at all? The answer is “gene
conversion” [168]. When autosomes recombine during normal meio-
sis, DNA is exchanged in a way that the accumulated mutational er-
rors of life get corrected in the germ cells via this DNA exchange. In
a sense, the autosomes have “sex” with each other. This correctional
meiosis cannot occur with the Y chromosome. Instead, the Y has
“sex” with itself. That is, during meiosis, the like sequence repeatsof the Y just “recombine” in a sense with each other, and that is the
function of the palindromes.
3.5.6. The Y chromosome and spermatogenesis in humans and in apes
Most intriguing is to compare the human Y chromosome to the
chimpanzee Y chromosome, both of which have been fully and accu-
rately sequenced [127,179–181]. Some interesting differences are
noted between the human Y and the chimpanzee Y [181]. Firstly,
the chimpanzee Y has many more amplicons and palindromes than
the human, but nonetheless it has much fewer ampliconic genes
(25 compared to 60). So the increased sperm production of chimpan-
zees cannot simply be explained by the presence of more testis specif-
ic genes on their Y chromosome. But interestingly, the chimpanzee Y
is missing a gene (PRY) that is present on AZFc in two copies in the
human. Speculatively, the PRY gene, which humans have and chim-
panzees do not have, could be a suppressor of spermatogenesis. It is
fascinating that this gene has also been found to be present in only
one copy in rare humans who have incredibly high sperm counts,
approaching half a billion [182].
3.5.7. Other male infertility genes not on the Y chromosome
Although most research into the genetics of male infertility has fo-
cused on the Y chromosome. Its counterpart, the X chromosome, also
seems to be an ideal locus for spermatogenesis genes. Like the Y chro-
mosome, the X chromosome is present as a single copy in the heteroga-
metic XYmale. Therefore, anymutation favorable to spermatogenesis is
more likely to spread and be expressed phenotypically in future gener-
ations of males if it is on the X.
Of course, in the egg, i.e., in the female, the X chromosome un-
dergoes normal meiosis and repair with its paired X mate, unlike
the Y. However, the X spends one-third of its evolutionary life in
the testis, and the X does not get to undergo normal meiotic repair
in the testis. So it cannot escape completely some of the problems
that the Y solves by constructing amplicons and palindromes. I
would suspect that ampliconic regions on the X-chromosome,
which have not yet been well characterized, could have a rich com-
plement of spermatogenesis genes. It seems very likely that evolution
has conferred on the human X chromosome also a large portion of the
burden for spermatogenesis [183].
3.5.8. What does the future hold?
It is commonly thought by laymen and others that the human ge-
nome has been completely sequenced. Of course this is not true. Rou-
tine shotgun sequencing is ineffective for elucidating ampliconic and
palindromic regions of multiple sequence repeats, such as dominate
the Y chromosome. It is certain that there are many ampliconic se-
quences throughout the genome that have not been elucidated.
Also, it is possible that with faster and cheaper sequencing of the en-
tire genome, the exome of the autosomes will reveal the rest of the
genes which control spermatogenesis.
3.6. Spermatogenic stem cell culture and transplantation to salvage
spermatogenesis in pre-pubertal boys about to undergo
sterilizing chemotherapy
It was ﬁrst shown by Ralph Brinster that spermatogenic stem cells
derived from the tissue of normal mice can be transferred via the rete
testis into mice with no spermatogenesis, and they will gradually pop-
ulate stem cell niches all along the seminiferous tubules of large areas
of the previously sterile recipient mouse testis and result in complete
spermatogenesis and ultimately in normal offspring [184,185]. Subse-
quently spermatogenic stem cells from a variety of species were suc-
cessfully transplanted into SCID mice. The closer the phylum of the
donor spermatogenic stem cells to the sterilized recipient mouse, the
farther along the spermatogenesis of the transplanted germ cells
would develop. For example, rat stem cells would develop mature
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than mouse spermatogenesis. For more distant phyla, the ﬁnal stages
of spermatogenesis are not seen although earlier stages are well
supported [186–190]. Frozen spermatogenic stem cells did just as well
as fresh [191]. In this ground breaking basic science work, Brinster's
lab set the stage for a potential clinical application for preserving fertil-
ity in cancer patients, particularly in pre-pubertal boys, and also set the
stage for amethod ﬁnally of the raising the sperm count of azoospermic
or severely oligospermic men [192,193].
Over the last three decades, effective cancer treatments have im-
proved the survival rates for many types of cancer. In children, the
survival rate for all cancers combined improved from 58% to 80%
[194]. Currently it is estimated that 1 in 250 young adults between
20 and 29 years of age is a long-term survivor of childhood cancer
[195,196]. The adverse side effects of their cancer treatment include
gonadal failure and sterility, and great efforts are now being made
to ﬁnd a way to prevent or modify these complications of cancer ther-
apy [197]. For post-pubertal boys or men, it is simple just to cryopre-
serve mature sperm found in ejaculate [198]. For girls or women
ovarian cortical strips can be cryopreserved [199]. But for prepubes-
cent boys, the only way to preserve their future fertility is through
testis biopsy, spermatogonial stem cell culture and ampliﬁcation,
cryopreservation of spermatogonial stem cells, and their subsequent
transfer back to the patient when he is an adult [200–204].
Recent studies have shown that long-term culture of spermato-
genic stem cells prior to transplanting via efferent ducts or rete testis
to a sterile recipient allows their ampliﬁcation in number so as to get
a better ultimate result [192,202,205,206]. Since these stem cells
represent .03% of germcells and 1.25% of spermatogonia, in vitro culture
and ampliﬁcation of cryopreserved spermatogenic stem cells will allow
this clinical application of preserving fertility for pre-pubertalmale can-
cer patients, and possibly some day of converting very oligospermic or
azoospermic males to normospermia.
4. Conclusion
In summary, what are the new science-based treatments on the
horizon for fertility? New technology in cryopreservation via vitriﬁca-
tion allows us to remove ovary tissue and freeze it to protect it from
sterilizing cancer treatment in young women, as well as to freeze in-
dividual mature eggs. It also allows us to stop the aging of the ovary
and eggs, which is the single major cause of the current worldwide
infertility epidemic. For the nagging problem of the older woman, a
milder increase in FSH allows better quality eggs to be retrieved for
women in their 40s at a more affordable cost and less effort. Thus
multiple cycles can be performed for retrieval of only the few best
eggs, accumulated and stored up over a year by vitriﬁcation, and
eventually achieve pregnancy rates similar to that of young women.
Although ICSI would seem to be already a very mature and
established treatment, the role of sperm quality in determining ICSI
results has been obscure. By establishing that epididymal sperm
yields better results than testis sperm, we are just beginning to tap
into this question. Results of ICSI for azoospermic men show that tes-
tis sperm are indeed inferior to epididymal sperm regardless of
quality or quantity of spermatogenesis. Sequencing of the X and Y
chromosomes reveal that spermatogenic genes are concentrated in
remarkable ampliconic repeat stretches of DNA in the Y chromosome
and we predict a similar concentration of spermatogenic genes on the
X chromosome and throughout the rest of the genome. This new mo-
lecular information explains why conventional treatments to raise
sperm count fail, and also why 60% of even azoospermic men have
minute amounts of sperm. Finally, spermatogenic stem cell culture
and transplantation in humans can preserve the fertility of prepuber-
tal boys about to undergo cancer treatment, and also by means of
stem cell ampliﬁcation can increase sperm count even in severely
oligospermic or azoospermic men.5. Addendum
There are other areas of future promise for fertility treatment that
are either more speculative, or are beyond this author's area of exper-
tise. I personally ﬁnd to be useless the very numerous “reviews” of lit-
erature, even with statistically valid meta-analysis, which are outside
of the personal experience and true expertise of the author. There-
fore, I have not included such review in this closing chapter except
for this addendum. I will brieﬂy mention them here, along with opin-
ions about their potential future value, however useless those opin-
ions might be.
The potential clinical treatment application of sequencing the X
and Y chromosomes in infertile men is often questioned. Will it lead
to ﬁnding a genetic cause in all men? Will it lead to genetic or other
treatments for male infertility like germ line therapy, or new drugs?
That question, often asked, is like asking Einstein whether his 1905
paper would eventually lead to television, or whether silicone re-
search in the 40s would lead to iPhones and iPads. The future practi-
cal value of understanding a phenomenon is often very clouded and
such speculation can be foolish. But I can be absolutely 100% certain
that there will eventually be a practical use in male infertility man-
agement for our sequencing of the X and the Y chromosomes and in-
deed re-sequencing the whole genome to get accurate information
about the heretofore hidden blank spots.
Pre-implantation genetic diagnosis (PGD) or screening (PGS) is
being promoted more and more furiously. No one doubts its value
for single gene disorders. But its value for chromosomal screening of
embryos for chromosomal errors has been disappointing. Random-
ized prospective control studies have shown day 3 biopsy with FISH
evaluation of blastomeres to be useless, and indeed harmful. Lately,
however, with the new technology of trophectoderm laser assisted
blastocyst biopsy and molecular karyotyping via whole genome am-
pliﬁcation and either comparative genomic hybridization (CGH) or
single nucleotide polymorphism (SNP) arrays, the concept of PGS is
now being re-energized. But the true practical value of this fascinat-
ing ﬁeld may be dismissed with a simple “thought experiment”: you
simply cannot improve pregnancy rate with selection. You can only
decrease the pregnancy rate by either an error in diagnosis or by
damage to the biopsied embryo. But you cannot improve the ultimate
pregnancy rate over simply vitrifying and eventually transferring all
the embryos.
The biggest practical question for futuristic treatments is whether
women will take advantage of our ability to preserve their fertility
with egg or ovary freezing at a young age, in their early or mid-
twenties. The technology is proven and available for ending the infertil-
ity epidemic. But we typically see only 35–40 year old women, often
who have just broken up with their boyfriend, come to clinic to request
fertility preservation, when in truth in the modern era, every woman
over 21 years of age should be given this opportunity if she so chooses.
But none of them do.References
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